biomedical research centre cambridge

Study at Cambridge

About the university, research at cambridge.

• Undergraduate courses
• Events and open days
• Fees and finance
• Postgraduate courses
• How to apply
• Postgraduate events
• Fees and funding
• International students
• Continuing education
• Executive and professional education
• Courses in education
• How the University and Colleges work
• Term dates and calendars
• Visiting the University
• Annual reports
• Equality and diversity
• A global university
• Public engagement
• Give to Cambridge
• For Cambridge students
• For our researchers
• Business and enterprise
• Colleges & departments
• Email & phone search
• Museums & collections
• Department of Oncology
• About us overview
• Department of Oncology sites
• How to find us
• Facilities overview
• Cambridge Biomedical Campus
• Leisure and Social
• Athena SWAN
• People overview
• Central Operations Team
• Research Leaders
• Academic Consultants
• Clinical Lecturers
• Postgraduate Student Supervisors
• Postgraduate Students
• Clinical Research Training Fellows
• Research overview
• Our Research overview
• Jean Abraham
• Richard Baird
• Bristi Basu
• Jamie Blundell
• Jason Carroll
• Charlotte Coles
• Mireia Crispin
• Harveer Dev
• Alison Dunning
• Rebecca Fitzgerald
• Richard Gilbertson
• Greg Hannon
• Duncan Jodrell
• Siddhartha Kar
• Charlie Massie
• Daniel Munoz-Espin
• Simon Pacey
• Manav Pathania
• Anna Philpott
• Robert Rintoul
• Our Research Impact
• Patients overview
• Services, Treatments & Care
• Staff Who Work with Patients
• Clinical Trials in Cambridge overview
• The Addenbrooke’s Centre for Clinical Investigation
• Cambridge Cancer Trials Centre
• Cambridge Cancer Trials Unit
• Cambridge Experimental Cancer Medicine Centre
• Anglia Cancer Network
• Education & Training overview
• Postdoctoral Training
• Postgraduate
• Undergraduate
• Clinical Academic Training
• Clinical Training
• Summer Students & Internships
• Seminars overview
• Lectures in Cancer Biology Series
• CRUK Cambridge Centre Talks
• CRUK Cambridge Institute Seminars
• News & Events
• Jobs & Studentships
• For Staff & Students overview
• COVID-19 Information & Guidance
• Departmental Key Contacts
• Committees & Representatives overview
• Oncology Management Committee
• Equality, Positive Culture & Wellbeing Champions
• Health & Safety Committee
• Postgraduate Education Committees
• For Staff overview
• New Starters
• Current Staff
• Joint University and NHS Staff
• Parents and Carers
• Apply for Leave
• Appraisals, Performance & Progression
• University Services
• For Students overview
• New Students
• Students with Children
• Postgraduate Education Handbooks
• University Code of Practice for Research Students
• Attendance and Leave
• Working Whilst Studying
• Procedures, Forms & Documents
• For Postgraduate Student Supervisors
• Communications & Branding
• Financial Services overview
• Research Grants
• Expense Claims
• Procurement
• Green Issues
• Health & Safety overview
• University Latest Safety Notices
• Departmental Safety Policy
• Accident & Incident Reporting
• Risk Assessments
• Safety Training & Development
• Remote Working
• Travel & Working Away overview
• Pre-travel Checklist
• Travel Risk Assessment Forms
• University Travel Insurance Portal
• Additional Advice & Guidance
• IT Services overview
• Assistive Technology
• Library Services
• LinkedIn Learning at Cambridge Hub
• Personal Development
• Research Management overview
• Open Access
• Impact Reporting Systems
• Data Management
• Governance & Integrity
• Research Excellence Framework 2021
• Contact form
• Key Contacts

The Cambridge Biomedical Research Campus is a partnership between the Cambridge University Teaching Hospital, Cambridge University and the Medical Research Council and is situated on the Addenbrooke's Hospital site.

The Campus encompasses the Cambridge University Hospitals, a number of University departments, several research institutes and pharmaceutical companies and is an internationally respected centre for patient care, biomedical research and education.

Addenbrooke's Hospital is one of the country's leading hospitals, rated by the Care Quality Commission for providing excellent quality of services and excellent use of resources. It is a centre for specialist care and a provider of local services, with a world-wide reputation as one of the foremost university teaching hospitals.

The laboratory and clinical research institutes at the Campus include the world famous MRC Laboratory for Molecular Biology, the Hutchison/MRC Research Centre, the Cancer Research UK Cambridge Institute and the Cambridge Institute for Medical Research. 

Information about the ongoing development of the Cambridge Biomedical Campus can be found here:  http://cambridge-biomedical.com/

Latest news

Rebecca Fitzgerald receives OBE for services to cancer

6 March 2023

Daniel Muñoz Espín wins PROSE award

Harveer Dev awarded $1 million Challenge grant from the Prostate Cancer Foundation

17 February 2023

View all news

Lectures in Cancer Biology

• Thu 18 Jul 09:30: Leveraging the Virtuous Cycle: Clinical Trials - Translational Science - Basic Science 22 Apr 2024

Quick links

• School of Clinical Medicine
• University Information Services (UIS)
• University key contacts
• Moodle login
• Information provided by:     [email protected]
• Site Privacy & Cookie Policies
• Terms and conditions
• Accessibility

© 2024 University of Cambridge

• Contact the University
• Freedom of information
• Privacy policy and cookies
• Statement on Modern Slavery
• University A-Z
• Research news
• About research at Cambridge
• Spotlight on...

Study at Cambridge

About the university, research at cambridge.

• Undergraduate courses
• Events and open days
• Fees and finance
• Postgraduate courses
• How to apply
• Postgraduate events
• Fees and funding
• International students
• Continuing education
• Executive and professional education
• Courses in education
• How the University and Colleges work
• Term dates and calendars
• Visiting the University
• Annual reports
• Equality and diversity
• A global university
• Public engagement
• Give to Cambridge
• For Cambridge students
• For our researchers
• Business and enterprise
• Colleges & departments
• Email & phone search
• Museums & collections

Wellcome-MRC Cambridge Stem Cell Institute

• About us overview
• Our building overview
• How to find us
• Art at JCBC overview
• Anna Brownsted
• Victoria Morton
• Harold Offeh
• Kelly Briggs
• Public engagement overview
• Reaching beyond Cambridge
• Connecting with local communities
• Giving patients a voice
• Creating an open and engaged research culture
• Under the Microscope
• What would you become?
• Equity, diversity & wellbeing
• For current students
• People overview
• Leadership & governance overview
• Postgraduate Education Committee
• Professional services
• Principal investigators overview
• Dr Maria Alcolea
• Professor Roger Barker
• Dr Thorsten Boroviak
• Dr Harry Bulstrode
• Dr Maria Duque-Correa
• Professor Cédric Ghevaert
• Professor Bertie Göttgens
• Professor Tony Green
• Dr Brian Hendrich
• Dr Daniel Hodson
• Professor Brian Huntly
• Professor Thóra Káradóttir
• Professor Walid Khaled
• Professor Elisa Laurenti
• Dr Joo-Hyeon Lee
• Professor Andrew McCaskie
• Professor Simón Méndez-Ferrer
• Dr Jyoti Nangalia
• Professor Anna Philpott
• Professor David Rowitch
• Dr Fotios Sampaziotis
• Professor Ben Simons
• Professor Sanjay Sinha
• Dr Mekayla Storer
• Professor Sarah Teichmann
• Dr Richard Tyser
• Dr Konstantinos Tzelepis
• Professor George Vassiliou
• Professor Matthias Zilbauer
• Affiliated principal investigators overview
• Dr Irving Aye
• Dr Srinjan Basu
• Dr Sumru Bayin
• Professor Serena Best
• Professor Allan Bradley
• Professor Sarah Bray
• Professor Ruth Cameron
• Dr Peter Campbell
• Dr Maria Christophorou
• Dr Ana Cvejic
• Professor Anne Ferguson-Smith
• Professor Sarah Franklin
• Professor Kristian Franze
• Professor Richard Gilbertson
• Dr Namshik Han
• Professor Muzlifah Haniffa
• Dr Phil Jones
• Dr Golnar Kolahgar
• Dr Mark Kotter
• Dr András Lakatos
• Professor Madeline Lancaster
• Professor Ernest Laue
• Professor Paul Lehner
• Dr Florian Merkle
• Professor James Nathan
• Professor Kathy Niakan
• Professor Ewa Paluch
• Dr Manav Pathania
• Dr Emma Rawlins
• Dr Teresa Rayon
• Dr Peter Rugg-Gunn
• Dr Marta Shahbazi
• Professor Azim Surani
• Dr Martin Turner
• Dr Jelle van den Ameele
• Professor Ludovic Vallier
• Professor Alan Warren
• Professor Doug Winton
• Academic & research staff
• Research overview

SCI-TIF - Technology & Innovation Forum

• Stem cell states
• Stem cells in disease
• Stem cells & therapeutics

Our COVID-19 research

• Clinical trials
• Interdisciplinary Research Centre overview
• Cambridge Centre for Myelin Repair overview
• CCMR PI and Affiliates
• Research culture and integrity overview
• Open access & Plan S
• Guidelines and Policies
• Pluripotency platforms
• Core facilities overview
• Bioinformatics
• Electron microscopy
• Genomics overview
• Submission guidelines
• Flow cytometry
• Single cell platforms
• Tissue culture
• Events overview
• 2024 CSCI Annual Retreat
• International Seminars overview
• Group Leader Seminars overview
• PhD and Postdoc Seminars overview
• Research Culture & Integrity Seminars overview
• Past Events
• Haematology Event: Cambridge Lymphoma Biology International Symposium
• Learn more overview
• Patient information
• Join us overview
• Students overview
• Wellcome-funded Four Year (MRes + PhD) Programme in Stem Cell Biology & Medicine overview
• Application Process and Eligibility
• Students: Past & Present
• 1+3 Stem Cell Programme Statistics
• MPhil in Biological Science (Stem Cell Biology)
• PhD in Biological Science (Stem Cell Biology)
• Other funding opportunities
• Work experience & internships
• Equality, diversity & wellbeing (students)
• FAQs for Wellcome studentships
• Institute Only overview

Interdisciplinary research centre

Our Stem Cells IRC facilitates interdisciplinary interactions across the University and the wider community of Cambridge researchers whose work has significance to stem cell research and therapeutics.

Cambridge Stem Cell Institute Technology & Innovation Forum (SCI-TIF) This bespoke new programme brings together scientists with an interest in stem cells and technology in order to foster rich discussions, partnerships and translational opportunities. What is SCI-TIF? A membership programme...

Made The Same Way: developmental biology podcast

This podcast from Reform Radio and the Wellcome-funded Human Developmental Biology Initiative brings together emerging artists and researchers to discuss science, life, and music.

Institute researchers are involved in COVID-19 research projects, working collaboratively with researchers across the University of Cambridge and at other institutions in the UK and beyond.

Latest news

‘Exhausted’ immune cells in healthy women could be target for breast cancer prevention in new study by the Khaled Group

28 March 2024

Researchers at CSCI and University of Cambridge have created the world’s largest catalogue of human breast cells, which has revealed early cell changes in healthy carriers of BRCA1 and BRCA2 gene mutations. The study, published today (28 March) in the journal Nature Genetics from r esearchers in the Khaled Group in the...

CSCI Hot Topic Event covers AI’s impact on stem cell research & medicine

20 March 2024

This week (Monday 18 March) , members of the Cambridge Stem Cell Institute, the Technology and Innovation Forum ( SCI-TIF ) and guests from around Cambridge convened to delve into the pressing subject of AI’s role in advancing stem cell research and medicine ( see the poster here ). The event began with a welcome by...

Degree of cell crowding in the early human embryo influences cell identity decision, new culture system finds

8 March 2024

Research published this week in Science Advances by Dr Shota Nakanoh in a collaboration between Dr Teresa Rayon’s lab at the Institute and Professor Ludovic Vallier’s lab at the Wellcome-MRC Cambridge Stem Cell Institute has determined that the degree of cell crowding in the early human embryo influences whether cells...

New UKRI funding co-led by Walid Khaled will support research into better health, ageing, and wellbeing

12 February 2024

Professor Walid Khaled from CSCI and co-leader Dr Laura Greaves from Newcastle have received UKRI funding for research on age-related biological changes in model organisms as part of a national collaboration. UKRI funding of £3 million is awarded today (12 February) to support a new research cluster as part of the MRC...

View all news

The Cambridge Stem Cell Institute is a world-leading centre for stem cell research.  

Our mission is to transform human health through a deep understanding of stem cell biology.  , we're funded by wellcome and the medical research council..

• 13 May CSCI PhD and Postdoc Seminar - Tekle Pauzaite & TBC
• 20 May CSCI PhD and Postdoc Seminar - Lottie Grey-Wilson & Eman Khatib-Massalha
• 22 May CSCI International Seminar - Prof. Richard White
• 03 Jun CSCI PhD and Postdoc Seminar - JaeHak Bang & Bart Theeuwes
• 10 Jun CSCI PhD and Postdoc Seminar - Cortina Chen &

View all events

Stay connected

Sign up to our newsletter to stay up to date with news and events from the Cambridge stem cell community.

Log into your account to see

Tweets by SCICambridge

athena-swan-silver-award.png

Jeffrey Cheah Biomedical Centre Puddicombe Way Cambridge Biomedical Campus CB2 0AW

[email protected]

Social media

Quick links

Logo and brand guidelines

Data protection policies

Site privacy and cookie policies

Our funders

Medical Research Council

© 2024 University of Cambridge

• Contact the University
• Accessibility
• Freedom of information
• Privacy policy and cookies
• Statement on Modern Slavery
• Terms and conditions
• University A-Z
• Undergraduate
• Postgraduate
• Research news
• About research at Cambridge
• Spotlight on...

View the latest institution tables

View the latest country/territory tables

NIHR Cambridge Biomedical Research Centre (Cambridge BRC), United Kingdom (UK)

Overall research output.

Overall Count and Share for 'NIHR Cambridge Biomedical Research Centre (Cambridge BRC)' based on the 12-month time frame mentioned above.

View all articles

Research outputs by subject area

Note: Articles may be assigned to more than one subject area. Hover over the donut graph to view the Share for each subject.

Compare with other institutions

Nature Strategy Reports

Identify research insights to guide research strategy and grow your impact with our Nature Strategy reports.

Actionable insights into research performance.

Detailed analysis of strengths and weaknesses.

Covers all major disciplines and regions of the world.

Nature Navigator

Data-driven insights for informed research strategy decisions with AI summarisation technology.

Track trends, summarise articles effortlessly.

Spark serendipitous discoveries.

Uncover collaboration opportunities.

Collaboration

International vs domestic collaboration by share.

Note: Hover over the graph to view the percentage of collaboration.

Top 5 domestic collaborators with NIHR Cambridge Biomedical Research Centre (Cambridge BRC) by Share

Collaborating institutions

Top 5 international collaborators with NIHR Cambridge Biomedical Research Centre (Cambridge BRC) by Share

Related news.

Advertisement

Latest supplement

Nature index 2024 health sciences.

More money is being spent on medical R&D than ever before, but with few new drugs to show for it. The race is on to find technological solutions that will speed up drug development and deliver better clinical outcomes. Nature Index Health Sciences 2024 highlights the people and projects that are bringing fresh perspectives to some of the most complex challenges in medicine and provides an in-depth look at how one country – the United States – is dominating the field.

Relationships

Nihr cambridge biomedical research centre (cambridge brc).

• NIHR Bioresource

Partner Institutions

NIHR Cambridge Biomedical Research Centre (Cambridge BRC) is a research collaboration whose article contributions are accrued to its participating partner institutions below.

• Cambridge University Hospitals NHS Foundation Trust
• University of Cambridge

Affiliated joint institutions and consortia

• DIAGRAM Consortium
• Multiple Tissue Human Expression Resource Consortium (MuTHER)

Home » Cancer

This theme’s focus:

• Early Detection and Diagnosis

Integrated Cancer Medicine

• New treatments and trials

In the UK, 1 in 2 people born after 1960 will be diagnosed with some form of cancer during their lifetime. Although diagnosis and treatment is improving, every year 167,000 people die of cancer in the UK .

The NHS Long-Term Plan wants to find ways to diagnose and treat cancer earlier and more precisely, so that 55,000 more people each year are able to survive cancer for more than 5 years following their diagnosis. Delivering this goal will be challenging. It will require collaboration between scientists, industry partners and the NHS to develop new ways to detect tumours, discover new therapies, and deploy new technologies, such as genomic medicine, artificial intelligence and machine learning (AI/ML) to create more efficient and precise treatment pathways for people with cancer.

The Cancer theme is based within the Cancer Research UK Cambridge Centre . We unite more than 1000 world-leading biologists, chemists, physicists, engineers, mathematicians, computer scientists, social scientists, clinicians, nurses and allied healthcare professionals across Cambridge to tackle cancer from every angle.

Our mission is to end death and disease caused by cancer through research, treatment and education.

We are detecting cancer at its earliest stage and developing personalised treatments for every patient, by facilitating new collaborations and driving the translation of new scientific discoveries into clinical applications to improve patient care. By working together across a range of different disciplines, our members are breaking down the barriers between the laboratory and the clinic, enabling patients to benefit from the latest innovations in cancer science.

In partnership with Addenbrooke’s and the University of Cambridge we are developing a new Cambridge Cancer Research Hospital to connect outstanding clinical expertise with world-class science and commercial innovation. We are creating a template for embedding early diagnosis and personalised treatment of cancer across the NHS.

Our research is enabled and enhanced by our thriving Patient and Public Involvement and Engagement (PPIE) group that meets regularly to review and advise all subtheme research. Patient members are included on trial steering committees and have been integral to the design of our new Cambridge Cancer Research Hospital.

The Cancer theme is addressing these national challenges and ambitions by finding new ways for:

Early Detection

Understanding early cancer biology, creating new diagnostics, and developing cancer risk prediction tools to diagnose cancer earlier and identify ways to treat it with less-invasive and more cost-effective treatments.

Developing ways to acquire, curate and integrate massive patient datasets using artificial intelligence and machine learning (AI/ML) approaches to improve real-time clinical decision-making.

New Treatments and Trials

Better use of existing treatments, including de-escalating therapy where safe and appropriate, and inventing new treatments by translating drug discoveries into clinical trials.

Credit: Photos from Cancer Research UK

• Contact details
• Our research: case studies
• Publications
• Our research – case studies

NIHR BioResource

Discover all about NIHR BioResource

Copyright ©2024 Cambridge Biomedical Research Centre Privacy policy Website design: VA Associates

Sign up to the CBC Weekly Update

For all the latest campus news

— Head to the News & Updates page to sign up

Campus Awarded Life Sciences Opportunity Zone Status

— Read more

Locate your business to the Campus

Discover the new phase at CBC

Discoveries

On the cutting edge of new discoveries and challenges.

— Discoveries

Explore your creativity with our three Artists-in-Residence 

— Read more  

We are creating a vibrant and groundbreaking health care community at the forefront of science and medicine.

— View

Discover why CBC is right for you.

— Locate to CBC

Who’s on Campus

The opinion leaders of today and the breakthroughs of tomorrow are here on Campus.

— Campus Occupiers

Discoveries that change the world

Our latest news and events, cambridge festival is coming to the campus.

5th March 2024

Campus news, Events

With over 300 events across Cambridge, Cambridge Festival is back for 2024. CamFest runs from 13 March and 28 March…

BLOG: Understanding CBC Ltd’s purpose and aspirations

1st March 2024

Nick Kirby, Managing Director of CBC Ltd, explains where CBC Ltd came from, and where we are going… As we…

CBC Open Forum gives local people chance to learn more about the Campus

25th January 2024

Campus news

On 24 January 2024, CBC Ltd held it’s first Open Forum, inviting staff and local people to learn about our…

Read News & Events

Study at Cambridge

About the university, research at cambridge.

• For Cambridge students
• For our researchers
• Business and enterprise
• Colleges and Departments
• Email and phone search
• Give to Cambridge
• Museums and collections
• Events and open days
• Fees and finance
• Postgraduate courses
• How to apply
• Fees and funding
• Postgraduate events
• International students
• Continuing education
• Executive and professional education
• Courses in education
• How the University and Colleges work
• Visiting the University
• Annual reports
• Equality and diversity
• A global university
• Public engagement

Biomedical research excellence at Cambridge

Cambridge university hospitals nhs foundation trust, in partnership with the university of cambridge, has been designated as one of the government's new comprehensive biomedical research centres, and will receive substantial new research and development funding from the national institute for health research (nihr). .

Cambridge University Hospitals (Addenbrooke's and the Rosie) with the University's School of Clinical Medicine are one of the very few places in the UK that provides a centre of research excellence together with a complete clinical infrastructure.

The site, with the associated presence of the Medical Research Council, and now Cancer Research UK, is already a leading centre for biomedical research, and this award will enable us to develop our potential even further.

In the hospital, clinical teams work alongside world-class scientists and it is this co-existence of experience and expertise that fosters translational research - turning basic science into new drugs and new therapies to improve patient care.

In making the award the international panel of experts confirmed that the partnership between the Trust and the University is internationally excellent in translational research.

The Biomedical Research Centre will address major health priorities in cancer, cardiovascular disease, obesity diabetes and metabolic disorders, imaging, infection and immunity, genetics, musculoskeletal disorders, neurosciences, transplantation, women's health, and capacity development and training.

Professor Patrick Sissons, Regius Professor of Physic, said: "The need for the NHS and the University to work together has never been greater and our joint strengths will drive forward innovation in the prevention, diagnosis and treatment of ill health. This additional funding will help translate our excellent research into the clinic, and will provide an environment which will enable us to make the campus an academic health centre of international standing."

Dr Mary Archer, Chairman of the Trust, said: "We are delighted with the news. It is another significant milestone in our 2020 Vision, the joint plan devised by the Trust, the University and the MRC to develop our site into the Cambridge Biomedical Campus, a world-class centre for research and healthcare."

This work is licensed under a Creative Commons Licence . If you use this content on your site please link back to this page.

Read this next

Robotic nerve ‘cuffs’ could help treat a range of neurological conditions

AI speeds up drug design for Parkinson’s ten-fold

Strongest evidence to date of brain’s ability to compensate for age-related cognitive decline

Autistic individuals have increased risk of chronic physical health conditions across the whole body

Search news, sign up to receive our newsletter.

The University's news digest summarises news from and about the University of Cambridge. Enter your email address, confirm you are happy to receive our emails and then select 'Subscribe'.

I wish to receive the University's news digest by email.

The University of Cambridge will use your email address to send you our University news digest email up to three times per week. We are committed to protecting your personal information and being transparent about what information we hold. Please read our email privacy notice for details.

• Neuroscience
• School of Clinical Medicine

Connect with us

© 2024 University of Cambridge

• Contact the University
• Accessibility statement
• Freedom of information
• Privacy policy and cookies
• Statement on Modern Slavery
• Terms and conditions
• University A-Z
• Undergraduate
• Postgraduate
• Cambridge University Press & Assessment
• Research news
• About research at Cambridge
• Spotlight on...

Study at Cambridge

About the university, research at cambridge.

• Undergraduate courses
• Events and open days
• Fees and finance
• Postgraduate courses
• How to apply
• Postgraduate events
• Fees and funding
• International students
• Continuing education
• Executive and professional education
• Courses in education
• How the University and Colleges work
• Term dates and calendars
• Visiting the University
• Annual reports
• Equality and diversity
• A global university
• Public engagement
• Give to Cambridge
• For Cambridge students
• For our researchers
• Business and enterprise
• Colleges & departments
• Email & phone search
• Museums & collections

Cambridge Institute for Medical Research

• CIMR's 2022 Institute Report
• Leadership, management & governance
• Institute administration
• Institute culture
• Support our research
• Research Strategy
• Outputs, research translation & achievements
• Principal Investigators
• Facilities overview
• Flow Cytometry
• Structural & Computational biology
• Research Facility Staff
• Research Advances overview

Reversible assembly and disassembly of V-ATPase during the lysosome regeneration cycle

• The ALBORADA Drug Discovery Institute
• Institute Operations
• Research Assistants
• Research Associates and Fellows
• Postgraduate Students
• Studying at CIMR overview
• Information for prospective postgraduate students
• Student life at CIMR
• Masters in the Molecular Mechanisms of Human Disease
• Working at CIMR overview
• CIMR Postdoctoral Committee
• ISAC/M 2024
• Public Engagement Overview
• Public Engagement Vision
• Public Engagement Strategy overview
• Reaching Research 2024
• Intranet (CIMR only)

CIMR’s mission is to determine the molecular mechanisms of disease in order to advance human health.

Cimr research advances.

Lysosomes function as the terminal degradative compartment of a cell’s endocytic and autophagic pathways, and as a multifunctional signalling hub integrating the cell’s response to nutrient status...

The role of the AP-1 adaptor complex in outgoing and incoming membrane traffic

Adaptor protein (AP) complexes are an ancient family of heterotetramers, which select cargo for packaging into transport vesicles at various locations in the cell. The AP-1 adaptor is arguably the...

Single-cell transcriptomic analysis of human pleura reveals stromal heterogeneity and informs in vitro models of mesothelioma

The pleural lining of the thorax regulates local immunity and wound healing. Disruption of these functions induces fibrosis and in the case of exposure to asbestos, chronic irritation can cause...

Human cytomegalovirus degrades DMXL1 to inhibit autophagy, lysosomal acidification, and viral assembly

Human cytomegalovirus (HCMV) is a herpervirus which persistently infects over 60% of people worldwide. It is an important human pathogen and leading cause of congenital disease, affecting ~1/100...

Loss of WIPI4 in neurodegeneration causes autophagy-independent ferroptosis

The study of rare genetic diseases can be a valuable way of acquiring new biological insights A new paper from joint first authors Ye Zhu and Motoki Fujimaki investigates the mechanisms by which...

p300 nucleocytoplasmic shuttling underlies mTORC1 hyperactivation in Hutchinson-Gilford Progeria Syndrome

Deregulated mTOR signaling is implicated in many diseases, including neurodegeneration, as well as aging. Hutchinson-Gilford progeria syndrome (HGPS) is a rare sporadic autosomal dominant accelerated...

The IRE1β-mediated unfolded protein response is repressed by the chaperone AGR2 in mucin producing cells

Cells are challenged with a variety of stressful situations, one being the accumulation of unfolded proteins, which disrupt normal cellular functions and contribute to diseases like neurodegeneration...

Quantitative proteomics defines mechanisms of antiviral defence and cell death during modified vaccinia Ankara infection

Monkeypox virus (MPXV), the cause of the mpox disease, is a zoonotic orthopoxvirus endemic in Central and West Africa. Since May 2022, thousands of cases of mpox have been reported in >90 non-...

Latest news

CIMR PI to co-lead The National Translational Centre for Rare Respiratory Diseases

29 April 2024

The medical research charity LifeArc has announced the launch of four new Translational Centres for rare diseases. One of these, The National Translational Centre for Rare Respiratory Diseases, will...

Prof David Rubinsztein receives American Academy of Neurology Movement Disorders Research Award

22 April 2024

CIMR are delighted that Prof David Rubinsztein has been awarded the 2024 Movement Disorders Research Award by the American Academy of Neurology. This award recognizes an individual for outstanding...

Dr Jennifer Dickens awarded Action for Pulmonary Fibrosis Mike Bray Fellowship

11 April 2024

Lung conditions are the third biggest killer in the UK, but receive relatively small amounts of research funding. Less than 2% of public medical research funding goes to respiratory disease research...

View all news

New CIMR publications

Luzio lab (Molecular Biology of the Cell 2024)

Robinson lab (Journal of Cell Biology 2024)

Marciniak lab, in collaboration with Prof Rintoul (Royal Papworth Hospital) & Matthew Garnett (Sanger Institute) (European Respiratory Journal 2024)

Single-cell transcriptomic analysis of human pleura reveals stromal heterogeneity and informs  in vitro  models of mesothelioma

Weekes lab (Cell Host & Microbe 2024)

Rubinsztein lab (Nature Cell Biology 2024)

Loss of WIPI4 in neurodegeneration causes autophagy-independent ferroptosis  

p300 nucleocytoplasmic shuttling underlies mTORC1 hyperactivation in Hutchinson–Gilford progeria syndrome

Ron lab (The EMBO Journal, 2023) The IRE1β-mediated unfolded protein response is repressed by the chaperone AGR2 in mucin producing cells

Weekes lab (Nature Communications, 2023) Quantitative proteomics defines mechanisms of antiviral defence and cell death during modified vaccinia Ankara infection

Salje lab (mSphere, 2023) Orientia tsutsugamushi: comprehensive analysis of the mobilome of a highly fragmented and repetitive genome reveals the capacity for ongoing lateral gene transfer in an obligate intracellular bacterium | mSphere (asm.org)  

Woods lab (Journal of Medical Genetics, 2023) Evidence of a genetic background predisposing to complex regional pain syndrome type 1

Rayner/ Deane labs (Nature Communications, 2023) The structure of a Plasmodium vivax Tryptophan Rich Antigen domain suggests a lipid binding function for a pan-Plasmodium multi-gene family

Rubinsztein lab (Developmental Cell, 2023) Mammalian autophagosomes form from finger-like phagophores

Warren lab in a collaboration co-led with the Nangalia lab [Wellcome Sanger Institute; Cambridge Stem Cell Institute] and Kent lab [University of York] (Nature Communications, 2023) Convergent somatic evolution commences in utero in a germline ribosomopathy 

Weekes lab (Cell Reports, 2023) Proteomic analysis of circulating immune cells identifies cellular phenotypes associated with COVID-19 severity

Weekes lab in collaboration with Gewurz lab [Harvard Medical School] (Molecular Cell, 2023) An Epstein-Barr virus protein interaction map reveals NLRP3 inflammasome evasion via MAVS UFMylation

Griffiths lab (Science, 2023) Ectocytosis renders T cell receptor signaling self-limiting at the immune synapse

Rubinsztein lab (Neuron, 2023) Microglial-to-neuronal CCR5 signaling regulates autophagy in neurodegeneration

Deane lab (PNAS, 2023) Altered plasma membrane abundance of the sulfatide-binding protein NF155 links glycosphingolipid imbalances to demyelination

Warren lab (Nucleic Acid Res., 2023) Cryo-EM reconstruction of the human 40S ribosomal subunit at 2.15 Å resolution

Gershlick lab (J. Cell Biology, 2023) The exocyst complex is an essential component of the mammalian constitutive secretory pathway

Read lab (Acta Crystallographica Section D, 2023) Likelihood-based docking of models into cryo-EM maps

Ron lab in collaboration with Elisa De Franco and Andrew Hattersley [University of Exeter] (EMBO Mol. Med 2023) Infancy-onset diabetes caused by de-regulated AMPyla tion of the human endoplasmic reticulum chaperone BiP

Tweets by TheCIMR

Postal Address: CIMR, The Keith Peters Building, Hills Road, Cambridge, CB2 0XY

Information provided by: [email protected]

Site Privacy & Cookie Policies Privacy policy | University of Cambridge

© 2024 University of Cambridge

• Contact the University
• Accessibility
• Freedom of information
• Privacy policy and cookies
• Statement on Modern Slavery
• Terms and conditions
• University A-Z
• Undergraduate
• Postgraduate
• Research news
• About research at Cambridge
• Spotlight on...

The NIHR Cambridge Clinical Research Facility (CRF) is part of the National Institute for Health and Care Research (NIHR) and hosted by Cambridge University Hospitals NHS Foundation Trust .

Located on the Cambridge Biomedical Campus, we provide a suite of purpose-built, staffed facilities for delivery of experimental medicine and translational research across two sites, at Cambridge University Hospitals and Royal Papworth Hospital. Patients and the public can take part in studies testing the latest developments to transform healthcare. Our dedicated teams work with clinicians, scientists and industry partners, enabling the delivery of commercial and non-commercial experimental medicine studies in a wide range of specialties, with people of all ages.

We are one of 28 NIHR-funded clinical research facilities networked across the UK, enabling collaboration with other sites and access to additional expertise and research infrastructure. Our CRF co-founded, and provides senior leadership to, the UKCRF Network , which develops, shares and implements excellence in CRF operations, workforce development, industry engagement and public involvement to ensure the efficient and effective delivery of studies.

Areas Of Expertise

We are proud to have been delivering high quality clinical research for over 20 years. We have experience in all health specialties, with particular expertise in cancer, metabolic diseases, neurodegenerative conditions, cardiovascular and respiratory medicine.

We Are Part of the NIHR

The National Institute for Health and Care Research (NIHR) funds, enables and delivers world-leading health and social care research that improves people’s health and wellbeing, and promotes economic growth.

NIHR Clinical Research Facilities (CRFs) support the delivery of early-phase and complex studies in purpose built facilities in NHS hospitals.

The NIHR has awarded £161 million over five years to 28 CRFs across England to support the delivery of experimental medicine.

Our Collaborators

We are an intrinsic part of the Cambridge Biomedical Campus , one of the largest of its kind in Europe, which combines world-class biomedical research, patient care, education and industry on a single site.

Here we collaborate with a wide range of centres, organisations and people including:

• NHS Trusts, such as Cambridge University Hospitals NHS Foundation Trust ; Royal Papworth Hospital NHS Foundation Trust ; Cambridge and Peterborough NHS Foundation Trust .
• University of Cambridge, including: School of Clinical Medicine departments ; Office for Translational Research ; Wolfson Brain Imaging Centre ; Cambridge Institute for Therapeutic Immunology and Infectious Disease (CITIID) ; Cambridge Institute for Medical Research (CIMR) ; Herschel Smith Building for Brain and Mind Sciences and more.
• Other campus organisations including: Wellcome-MRC Institute of Metabolic Science Metabolic Research Laboratories ; Cancer Research UK Cambridge Centre ; Heart and Lung Research Institute ; Jeffrey Cheah Biomedical Centre; AstraZeneca ; GSK and more.

NIHR Infrastructure – Collaborations

We benefit from being part of the UK Clinical Research Facility (UKCRF) Network, which supports CRFs, both NIHR and non-NIHR-funded, to deliver clinical trials of the highest standard and promotes the UK as the place for investment in and economic growth from health research. Over 50 CRFs across the UK and Ireland are supported, working together to deliver networked experimental medicine at pace and driving forward initiatives that improve the quality of the patient experience. Read more about the UKCRF Network .

We work very closely with the NIHR Cambridge Biomedical Research Centre (BRC), which funds and supports ground-breaking clinical research in a wide range of clinical conditions. Approximately 85% of our studies are aligned with the Cambridge BRC themes. NIHR Biomedical Research Centres (BRCs) are collaborations between NHS organisations and universities. They bring together academics and clinicians to translate scientific discoveries into potential new treatments, diagnostics and technologies. Read more about NIHR BRCs .

We have a strong track record of delivering clinical studies designed to improve the detection and treatment of cancers, and we collaborate closely with the Cambridge Experimental Cancer Medicine Centre (ECMC). The ECMC initiative is jointly funded by Cancer Research UK, the NIHR in England and the Departments of Health for Scotland, Wales and Northern Ireland.

We are committed to supporting and working with the NIHR BioResource , which brings together researchers and willing volunteers to contribute to leading research.  The NIHR BioResource national coordinating centre is located in Cambridge and is hosted by Cambridge University Hospitals NHS Foundation Trust in partnership with the University of Cambridge.

Cambridge Clinical Research Facility (CRF) is the largest, single site NIHR CRF. It is located in the heart of the Cambridge Biomedical Campus, the largest centre of medical research and health science in Europe.

The NIHR Cambridge Clinical Research Facility (CRF) is part of the NIHR and hosted by  Cambridge University Hospitals NHS Foundation Trust .

Privacy Policy

Accessibility

NIHR Cambridge Clinical Research Facility Cambridge Clinical Research Centre Keith Day Road Cambridge Biomedical Campus Cambridge CB2 0SL

01223 254642

Email:  [email protected]

Privacy Overview

• Skip to content
• Skip to navigation
• Skip to footer

AstraZeneca in Cambridge

Home / Our company / Cambridge

The Discovery Centre (DISC)

A state-of-the-art global r&d facility located in the heart of the cambridge biomedical campus., cambridge, one of the most exciting bioscience hotspots in the world, is home to the largest uk research and development centre – the disc. here more than 2,300 scientists work in drug discovery and development, across our therapy areas, each playing a central role in our mission to deliver life-changing medicines to patients. the disc is uniquely designed to strengthen collaboration, promote openness, and improve the sustainability of every aspect of our science and our business operations..

We are at an exciting moment, as remarkable science and collaboration provide new opportunities to translate early discovery into meaningful medicines that can slow or even stop disease progression, prevent or even potentially cure disease. I look forward to the next chapter in BioPharmaceuticals, as we continue to push the boundaries of science and innovation to deliver life-changing medicines for use by patients across the world. Sharon Barr Executive Vice-President, BioPharmaceuticals R&D, AstraZeneca

Science in Pictures

Celebrating science and the power of what science can do., stem community art project.

We commissioned a giant art installation inspired by science, which was created by the People’s Picture in collaboration with our STEM community. It celebrates and recognises the role and impact of science through the medium of art and design.

The giant mosaic is an artistic interpretation of the building, DISC, the UK’s largest research and development centre. It is composed of over 8,000 pictures and 1,000 original images created by young people who attended inspirational science sessions in schools and community events hosted with our STEM partners.

Designing the future of R&D

The DISC represents our belief in what science can do. It enables scientists to discover new medicines more efficiently and deliver them more effectively, harnessing the power of data and artificial intelligence, digital technologies and novel precision medicine approaches.

Here, as in all our research efforts worldwide, we’ll be striving to enhance our understanding of disease biology, discover new ways to target drivers of disease, better predict clinical success, and pioneer new approaches to engagement in the clinic.

Our Cambridge culture

Located in the heart of the cambridge biomedical campus we are surrounded by scientific institutions, academia and world-leading hospitals. we believe that interaction, collaboration and an entrepreneurial approach are vital for accelerating science and re-imagining healthcare. ​.

Collaboration

• Collaboration and working in partnership across academia, biotech , and industry is key to advancing scientific innovation to transform healthcare and improve outcomes for patients.
• The power of our physical proximity to our Cambridge neighbours creates unusual interfaces in a porous environment where talent can be shared, not siloed. 

• Through our STEM programmes, we aim to inspire the next generation, exciting them about science and the wide range of opportunities available in our industry. 
• We aim to show that science can be for everyone, growing the aspirations of young people.  

• Our culture is inclusive, inventive, freed from the fear of failure.
• We ask big questions, make brave decisions and dig deep into the biology of complex disease.

By working with our neighbours and driving a convergence of innovation, collaboration and talent from the heart of the Cambridge Biomedical Campus and beyond, we continue to develop our culture and accelerate the science in our key therapy areas of Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology and rare diseases. Susan Galbraith Executive Vice-President, Oncology R&D, AstraZeneca

We believe that interaction, collaboration and an entrepreneurial approach are vital for accelerating science and re-imagining healthcare. Mene Pangalos Executive Vice-President, BioPharmaceuticals R&D, AstraZeneca (retiring, announced 28 July 2023)

A sustainable future

We are dedicated to making our science and our business sustainable. The DISC exemplifies this in every aspect of what we do – helping to protect the environment by how we operate our labs and discover, develop and produce our medicines.

Environmental sustainability formed the design principles of The DISC, focusing on increasing energy efficiency and working with the natural environment with an aim to reduce heating and lighting consumption by over 40%. The DISC has been awarded an excellent rating by BREEAM, the world’s leading sustainability assessment for building projects. Our scientists are working in a building that follows best practice in low energy design and construction, in support of our path to deliver Ambition Zero Carbon. This will help us to achieve our Company target to reduce greenhouse gas emissions from our global operations (Scope 1 and 2) by 98% by 2026.

Join AstraZeneca

and help us deliver life-changing medicines

Be among our employees who continue to make us an innovation-driven company that stands firmly among the worlds leaders in biopharmaceuticals

the best science doesn't happen in isolation

We partner with others around the world, combining the great science in our labs with complementary technologies, know-how and molecules to accelerate the delivery of new life-changing medicines.

Veeva ID: Z4-60207 Date of preparation: November 2023

You are now leaving AstraZeneca.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.

Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.

Important notice for users You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information. I have read this warning and will not be using any of the contained product information for clinical purposes.

Study at Cambridge

About the university, research at cambridge.

• Events and open days
• Fees and finance
• Student blogs and videos
• Why Cambridge
• Qualifications directory
• How to apply
• Fees and funding
• Frequently asked questions
• International students
• Continuing education
• Executive and professional education
• Courses in education
• How the University and Colleges work
• Visiting the University
• Term dates and calendars
• Video and audio
• Find an expert

Publications

• International Cambridge
• Public engagement
• Giving to Cambridge
• For current students
• For business
• Colleges & departments
• Libraries & facilities
• Museums & collections
• Email & phone search

MRC Epidemiology Unit

Professor nick wareham, director, programme leader and mrc investigator aetiology and mechanisms of diabetes and related metabolic disorders of later life.

Nick Wareham is the Director of the MRC Epidemiology Unit and co-Director of the Institute of Metabolic Science .

He is also the Director of the new national research network Population Health Improvement UK .

His principal research interests are the aetiology and prevention of obesity and diabetes, and he co-leads the Aetiology and Mechanisms of Diabetes and Related Metabolic Disorders of Later Life programme  with Dr Claudia Langenberg. He is an Honorary Consultant at Addenbrooke’s Hospital, Cambridge.

Nick was formerly a Wellcome Trust Senior Fellow in Clinical Science in Cambridge. He qualified in medicine from St Thomas’ Hospital Medical School, London, and trained in epidemiology and public health at the London School of Hygiene and Tropical Medicine, London, Harvard University, Boston, USA and at the University of Cambridge. Nick was Chair of the NICE Programme Development Group on the prevention of prediabetes.  In 2009 he was a member of the WHO Expert Group on the classification and diagnosis of diabetes.

Current work and interests

Nick undertakes research into the aetiological determinants of diabetes, obesity and related metabolic disorders, and the translation of that epidemiological understanding into preventive action. He is a Principal Investigator on the EPIC-Norfolk study and leads the working group for diabetes, obesity and physical activity in EPIC-Europe study. He is the co-ordinator of the InterAct EU FP6 funded project, which aims to investigate how genes and lifestyle factors interact to lead to type 2 diabetes. He has a programme of research into the genetic basis of obesity and type 2 diabetes as part of the Genetics of Energy Metabolism (GEM) consortium. His work on gene-environment interaction is based on quantitative trait studies and large scale population-based cohort studies. A key element of this work is the accurate measurement of lifestyle exposures including physical activity and he has developed and evaluated novel methods for measuring energy expenditure in free-living individuals in population-based studies. He is co-lead of the ADDITION study , a trial of screening for diabetes and intensive cardiovascular risk reduction undertaken in 3 European countries.

• MRC Epidemiology Unit publications on Publications Database .
• Nick’s Google Scholar page here.

Professional membership and roles

• MRCP (Membership of the Royal College of Physicians), 1990
• MFPHM (Membership of the Faculty of Public Health Medicine), 1992
• Accreditation in Public Health Medicine, 1995
• FRCP (Fellowship of the Royal College of Physicians), 2003
• FFPHM (Fellowship of the Faculty of Public Health Medicine), 2003
• Kroc Lecturer and Award, University of Uppsala, 2007
• Joseph J Hoet Memorial Lecturer and Menarini Award, 5 th World Congress on Prevention of Diabetes and its Complications, 2008
• Chair, NICE Programme Development Group on the prevention of prediabetes.
• BHF Chairs & Programme Grants Committee
• MRC Population Health Sciences Group
• NIHR Public Health Research Funding Board
• NICE Programme Development Group Type 2 Diabetes Mellitus
• MRC International Nutrition Group’s Scientific Advisory Committee (ING)
• BHF UK Physical Guidelines Co-ordination Group
• NETSCC HTA Obesity Themed Call Board
• MRC Initiative to establish UK Regional Hubs for Clinical Trials Methodology Research (HTMR)
• Office for Strategic Co-ordination of Health Research (OSCHR) PHRB Board
• DIAMAP Scientific Expert Advisory Board
• Diabetes UK Research Committee
• MRC National Survey Health and Development (NHSD) Board
• MRC Health Services and Public Health Research Board (PHROG)
• MRC Physical Systems and Clinical Services Board
• UKCRC Planning for Public Health Research in Physical Activity
• Editorial Board, Diabetologia

Recent Posts

• Rare gene variants conferring up to 6-fold increase in obesity risk hint at new mechanism affecting appetite control
• Prof Nick Wareham to play leading role in new national research network for population health
• AI predicts healthiness of food menus and highlights ‘double burden’ of unhealthy food environment in deprived areas
• HERA study to better understand women’s reproductive health receives £5.6 million Wellcome award
• Fenland Study helping uncover long term effects of pandemic on health behaviours

Information provided by:

[email protected] Site Privacy & Cookie Policies

Useful Links

Freedom of information, privacy policy, research integrity, website terms and conditions, social media, follow us on twitter, follow us on instagram, follow us on facebook, follow us on linkedin, subscribe on youtube.

© 2024 University of Cambridge

• University A-Z
• Contact the University
• Accessibility
• Freedom of information
• Terms and conditions
• Undergraduate
• Spotlight on...
• About research at Cambridge

Jump to navigation

• Our vision and strategy
• Our faculty and partners
• Our achievements
• Scientific Advisory Board
• Engaging our local community
• Acknowledging our funders

• CCTC Strategy
• Trials in development

• Current Trials
• All Current Trials
• Bio-Sampling Team
• Brain & CNS
• Gynaecological
• Haematological
• Head & neck
• Liver & Bile Duct
• Oesophageal
• Radiotherapy
• Skin & melanoma

• Advanced Cancer Imaging
• Programme Members
• Clinical trials
• Impact - ACI
• Jobs and PhDs
• Cancer Immunology
• Cambridge Cellular Therapy Lab
• Educational Resources
• Programme Partners
• Publications
• Pump Priming Awards
• Programme Home
• Nursing and AHP
• Ovarian Cancer
• Clinical Team
• Paediatric Cancer
• Research areas
• Pancreatic Cancer
• Thoracic Programme : Home
• Thoracic Programme : Members
• Thoracic Programme : Scientific Research
• Thoracic Programme : Clinical Research
• Thoracic Programme : News and Events
• Thoracic Programme : Publications
• Thoracic Programme : Steering Committee

• Brain Cancer Virtual Institute
• Breast Cancer Virtual Institute
• Precision Breast Cancer Institute
• Patient Involvement
• News archive
• Haematological Malignancies Virtual Institute
• Programme Updates
• Mark Foundation Institute for Integrated Cancer Medicine
• Urological Malignancies Virtual Institute
• Prostate cancer
• Renal cancer
• Programme Newsletters
• CRUK Cambridge Institute
• CRUK-Wellcome Gurdon Institute
• Early Cancer Institute
• The Milner Therapeutics Institute and Consortium

• Cancer Molecular Diagnostics Lab
• Cancer Core Europe
• Children's Brain Tumour Centre of Excellence
• CRUK RadNet Cambridge
• Radiotherapy Timeline
• CRUK Therapeutic Discovery Laboratories
• Experimental Cancer Medicine Centre (ECMC)
• Experimental Cancer Medicine Demystified 2023
• NIHR Biomedical Research Centre (BRC)
• Open Lab Initiative Home
• Express your interest in the Open Lab Initiative

• Black Leaders in Cancer PhD Scholarship Programme
• MRes + PhD Programme in Cancer Biology
• MRes + PhD studentships 2024
• Part time MRes + PhD in Cancer Biology for Clinician Scientists
• Current MRes/PhD Student Profiles
• ACED Early Detection PhD Studentship
• Info for current students

• Overview of clinical academic training
• Clinical Research Fellowships
• Clinical Research Training Fellow profile - Tumas Beinortas
• Clinical Research Training Fellow profile- Ashray Gunjur
• Clinical Research Training Fellow profile - Karen Pinilla

• Entrepreneurship summer school 2023
• Lectures in Cancer Biology and Medicine
• Overview of postdoctoral opportunities
• Undergraduate summer placement scheme
• Postdoctoral Mentorship Award
• Shared Risk Overview
• Lesson 1: Epidemiology and Risk
• Lesson 2: Developing a Risk Prediction Model
• Lesson 3: Validating a Risk Prediction Model
• Lesson 4: Risk Prediction in the Clinic
• Lesson 5: Anthropology and Situating Risk
• Lesson 6: Public Involvement in Risk
• Feedback Questionnaire

• News and events
• Listen to the Podcast
• Get involved! Submit a question
• Our Members

Search form

Centre-organised events

Early cancer institute seminar: professor sarah teichmann, camsoc2024 : cambridge symposium on oesophageal cancer - 2024.

• Our organisation
• Our members
• Trials designed in Cambridge
• Early Phase Trials
• Fundamental Biology of Cancer
• Nursing and Allied Health Professionals
• Thoracic Cancer
• Milner Therapeutics Institute and Consortium
• Cancer Molecular Diagnostics Lab (CMDL)
• Experimental Cancer Medicine Centre
• NIHR Cambridge Biomedical Research Centre
• Open Lab Initiative
• Shared Risk eLearning course

CRUK Cambridge Centre Cancer Research UK Cambridge Institute University of Cambridge Li Ka Shing Centre, Robinson Way Cambridge, CB2 0RE

Connect with us

[email protected] Twitter (CRUK Cambridge Centre) Twitter (Graduate Training)

About this site

Cookies Terms and Conditions Accessibility Sitemap Site by DC Systems Ltd

Cachd1 interacts with Wnt receptors and regulates neuronal asymmetry in the zebrafish brain

Affiliations.

• 1 Cell and Developmental Biology, Division of Biosciences, University College London, London WC1E 6BT, UK.
• 2 Wellcome Trust Sanger Institute, Cambridge CB10 1SA, UK.
• 3 Division of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.
• 4 Departments of Otolaryngology-HNS and Biological Structure, University of Washington, Seattle, WA 98195-7420, USA.
• 5 Ambry Genetics, Aliso Viejo, CA 92656, USA.
• 6 The Francis Crick Institute, London, NW1 1AT, UK.
• 7 Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, 08028 Barcelona, Spain.
• 8 Institute of Ophthalmology, University College London, London EC1V 9EL, UK.
• 9 Center for Integrative Biology, Facultad de Ciencias, Universidad Mayor, Camino La Piramide 5750, 8580745 Santiago, Chile.
• 10 St. George's, University of London, London SW17 0RE, UK.
• 11 Department of Biology, Hull York Medical School, York Biomedical Research Institute, University of York, York YO10 5DD, UK.
• PMID: 38696577
• DOI: 10.1126/science.ade6970

Neurons on the left and right sides of the nervous system often show asymmetric properties, but how such differences arise is poorly understood. Genetic screening in zebrafish revealed that loss of function of the transmembrane protein Cachd1 resulted in right-sided habenula neurons adopting left-sided identity. Cachd1 is expressed in neuronal progenitors, functions downstream of asymmetric environmental signals, and influences timing of the normally asymmetric patterns of neurogenesis. Biochemical and structural analyses demonstrated that Cachd1 can bind simultaneously to Lrp6 and Frizzled family Wnt co-receptors. Consistent with this, lrp6 mutant zebrafish lose asymmetry in the habenulae, and epistasis experiments support a role for Cachd1 in modulating Wnt pathway activity in the brain. These studies identify Cachd1 as a conserved Wnt receptor-interacting protein that regulates lateralized neuronal identity in the zebrafish brain.

Publication types

• Research Support, Non-U.S. Gov't
• Research Support, N.I.H., Extramural
• Brain / metabolism
• Frizzled Receptors / genetics
• Frizzled Receptors / metabolism
• Habenula* / embryology
• Habenula* / metabolism
• Loss of Function Mutation
• Low Density Lipoprotein Receptor-Related Protein-6 / genetics
• Low Density Lipoprotein Receptor-Related Protein-6 / metabolism
• Membrane Proteins / genetics
• Membrane Proteins / metabolism
• Neurogenesis*
• Neurons* / metabolism
• Receptors, Wnt / genetics
• Receptors, Wnt / metabolism
• Wnt Signaling Pathway*
• Zebrafish Proteins* / genetics
• Zebrafish Proteins* / metabolism
• Zebrafish* / genetics
• Zebrafish Proteins
• Low Density Lipoprotein Receptor-Related Protein-6
• Frizzled Receptors
• Receptors, Wnt
• Membrane Proteins